The clinical responses observed following treatment with immune checkpoint inhibitors
(ICIs) support immunotherapy as a potential anticancer treatment. However, a large …

Myeloid cells are pivotal within the immunosuppressive tumour microenvironment. The
accumulation of tumour-modified myeloid cells derived from monocytes or neutrophils …

Effectiveness of checkpoint immunotherapy in cancer can be undermined by
immunosuppressive tumor-associated macrophages (TAMs) with an M2 phenotype …

Neoadjuvant chemoimmunotherapy improves pathologic complete response rate and event-
free survival in patients with resectable non–small cell lung cancer (NSCLC) versus …

Anticancer agents continue to dominate the list of newly approved drugs, approximately half
of which are immunotherapies. This trend illustrates the considerable promise of cancer …

Tumor drug resistance emerges from the interaction of two critical factors: tumor cellular
heterogeneity and the immunosuppressive nature of the tumor microenvironment (TME) …

Accumulating research suggests that the tumor immune microenvironment (TIME) plays an
essential role in regulation of tumor growth and metastasis. The cellular and molecular …

Mutations in the STK11 (LKB1) gene regulate resistance to PD-1/PD-L1 blockade. This
study evaluated this association in patients with nonsquamous non–small cell lung cancer …

The tumor microenvironment (TME) is a complex and heterogeneous environment
composed of cancer cells, tumor stroma, a mixture of tissue-resident and infiltrating immune …

Cancer immunotherapy has dramatically changed the approach to cancer treatment. The
aim of targeting the immune system to recognize and destroy cancer cells has afforded …